July 31, 2018 - The court denied the defendants' motion to dismiss.

October 10, 2017 - A motion to dismiss the amended complaint was filed.

August 25, 2017 - An amended complaint was filed.

March 27, 2017 (Shareholders Foundation) - An investor in shares of OvaScience Inc (NASDAQ:OVAS) filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by OvaScience Inc in connection with certain allegedly false and misleading statements made between January 8, 2015 and March 26, 2015.

According to the complaint the plaintiff alleges on behalf of purchasers of OvaScience Inc (NASDAQ:OVAS) common shares between January 8, 2015 and March 26, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between January 8, 2015 and March 26, 2015, the defendants caused the Company to issue false and misleading statements and/or fail to disclose, among other things, that the science behind AUGMENT had not been scientifically validated, that the Company was unable to achieve the purported success rates it claimed, that the reasons why the Company moved its studies outside of the United States, and that at all relevant times, the Company's profitability and prospects were false and misleading.

Waltham, MA based OvaScience, Inc. is a global fertility company that is focused on the discovery, development and commercialization of fertility treatment options for women.

Shares of OvaScience Inc (NASDAQ:OVAS) declined from as high as $50.18 per share in January 2015 to as low as $1.34 per share in December 2016.